Reuters logo
BRIEF-Gilead Sciences presents results from late-stage study ‍​
2017年10月4日 / 下午1点18分 / 13 天前

BRIEF-Gilead Sciences presents results from late-stage study ‍​

Oct 4 (Reuters) - Gilead Sciences Inc:

* Gilead Sciences Inc - ‍no patients in bictegravir treatment arm demonstrated treatment-emergent resistance through 48 weeks​

* Gilead - ‍bictegravir-containing regimen is non-inferior to boosted protease inhibitor-based regimens in virologically suppressed adult hiv patients

* Gilead Sciences Inc - ‍one participant on drv/ritonavir + abc/3tc developed a treatment-emergent nrti mutation associated with abacavir​

* Gilead - presents results from phase 3 study evaluating patients who switched to a fixed-dose combination from boosted protease inhibitor-based regimens​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below